173 related articles for article (PubMed ID: 26022067)
1. Development of Global Consensus of Dengue Virus Envelope Glycoprotein for Epitopes Based Vaccine Design.
Hussain M; Idrees M; Afzal S
Curr Comput Aided Drug Des; 2015; 11(1):84-97. PubMed ID: 26022067
[TBL] [Abstract][Full Text] [Related]
2. Synthetic B-Cell Epitopes Eliciting Cross-Neutralizing Antibodies: Strategies for Future Dengue Vaccine.
Ramanathan B; Poh CL; Kirk K; McBride WJ; Aaskov J; Grollo L
PLoS One; 2016; 11(5):e0155900. PubMed ID: 27223692
[TBL] [Abstract][Full Text] [Related]
3. A computational approach for identification of epitopes in dengue virus envelope protein: a step towards designing a universal dengue vaccine targeting endemic regions.
Chakraborty S; Chakravorty R; Ahmed M; Rahman A; Waise TM; Hassan F; Rahman M; Shamsuzzaman S
In Silico Biol; 2010; 10(5-6):235-46. PubMed ID: 22430357
[TBL] [Abstract][Full Text] [Related]
4. [Mapping of the B Cell Neutralizing Epitopes on ED III of Envelope Protein from Dengue Virus].
Lin Y; Wen K; Guo Y; Qiu L; Pan Y; Yu L; Di B; Chen Y
Bing Du Xue Bao; 2015 Nov; 31(6):665-73. PubMed ID: 26951013
[TBL] [Abstract][Full Text] [Related]
5. Comparison of Neutralizing Dengue Virus B Cell Epitopes and Protective T Cell Epitopes With Those in Three Main Dengue Virus Vaccines.
Pinheiro JR; Camilo Dos Reis E; Souza RDSO; Rocha ALS; Suesdek L; Azevedo V; Tiwari S; Rocha BGS; Birbrair A; Méndez EC; Luiz WB; Amorim JH
Front Immunol; 2021; 12():715136. PubMed ID: 34489965
[TBL] [Abstract][Full Text] [Related]
6. Immunoinformatics design of a novel epitope-based vaccine candidate against dengue virus.
Fadaka AO; Sibuyi NRS; Martin DR; Goboza M; Klein A; Madiehe AM; Meyer M
Sci Rep; 2021 Oct; 11(1):19707. PubMed ID: 34611250
[TBL] [Abstract][Full Text] [Related]
7. Elaboration of tetravalent antibody responses against dengue viruses using a subunit vaccine comprised of a single consensus dengue envelope sequence.
Sun J; Li M; Wang Y; Hao P; Jin X
Vaccine; 2017 Nov; 35(46):6308-6320. PubMed ID: 28987441
[TBL] [Abstract][Full Text] [Related]
8. Identification of continuous human B-cell epitopes in the envelope glycoprotein of dengue virus type 3 (DENV-3).
da Silva AN; Nascimento EJ; Cordeiro MT; Gil LH; Abath FG; Montenegro SM; Marques ET
PLoS One; 2009 Oct; 4(10):e7425. PubMed ID: 19826631
[TBL] [Abstract][Full Text] [Related]
9. An Envelope-Modified Tetravalent Dengue Virus-Like-Particle Vaccine Has Implications for Flavivirus Vaccine Design.
Urakami A; Ngwe Tun MM; Moi ML; Sakurai A; Ishikawa M; Kuno S; Ueno R; Morita K; Akahata W
J Virol; 2017 Dec; 91(23):. PubMed ID: 28956764
[TBL] [Abstract][Full Text] [Related]
10. Optimization of Surface Display of DENV2 E Protein on a Nanoparticle to Induce Virus Specific Neutralizing Antibody Responses.
Coffman JE; Metz SW; Brackbill A; Paul M; Miley MJ; DeSimone J; Luft JC; de Silva A; Tian S
Bioconjug Chem; 2018 May; 29(5):1544-1552. PubMed ID: 29701995
[TBL] [Abstract][Full Text] [Related]
11. An adenovirus type 5 (AdV5) vector encoding an envelope domain III-based tetravalent antigen elicits immune responses against all four dengue viruses in the presence of prior AdV5 immunity.
Khanam S; Pilankatta R; Khanna N; Swaminathan S
Vaccine; 2009 Oct; 27(43):6011-21. PubMed ID: 19665609
[TBL] [Abstract][Full Text] [Related]
12. Identification and characterization of a linearized B-cell epitope on the pr protein of dengue virus.
Song KY; Zhao H; Li SH; Li XF; Deng YQ; Wang HJ; Ye Q; Zhu SY; Jiang ZY; Zhang FC; Qin ED; Qin CF
J Gen Virol; 2013 Jul; 94(Pt 7):1510-1516. PubMed ID: 23559476
[TBL] [Abstract][Full Text] [Related]
13. Inferring Protective CD8+ T-Cell Epitopes for NS5 Protein of Four Serotypes of Dengue Virus Chinese Isolates Based on HLA-A, -B and -C Allelic Distribution: Implications for Epitope-Based Universal Vaccine Design.
Shi J; Sun J; Wu M; Hu N; Li J; Li Y; Wang H; Hu Y
PLoS One; 2015; 10(9):e0138729. PubMed ID: 26381649
[TBL] [Abstract][Full Text] [Related]
14. Synthetic peptides containing B- and T-cell epitope of dengue virus-2 E domain III provoked B- and T-cell responses.
Li S; Peng L; Zhao W; Zhong H; Zhang F; Yan Z; Cao H
Vaccine; 2011 May; 29(20):3695-702. PubMed ID: 21419774
[TBL] [Abstract][Full Text] [Related]
15. Exploring dengue genome to construct a multi-epitope based subunit vaccine by utilizing immunoinformatics approach to battle against dengue infection.
Ali M; Pandey RK; Khatoon N; Narula A; Mishra A; Prajapati VK
Sci Rep; 2017 Aug; 7(1):9232. PubMed ID: 28835708
[TBL] [Abstract][Full Text] [Related]
16. The Immunodominance Change and Protection of CD4+ T-Cell Responses Elicited by an Envelope Protein Domain III-Based Tetravalent Dengue Vaccine in Mice.
Chen HW; Hu HM; Wu SH; Chiang CY; Hsiao YJ; Wu CK; Hsieh CH; Chung HH; Chong P; Leng CH; Pan CH
PLoS One; 2015; 10(12):e0145717. PubMed ID: 26714037
[TBL] [Abstract][Full Text] [Related]
17. Identification and selection of immunodominant B and T cell epitopes for dengue multi-epitope-based vaccine.
Lim HX; Lim J; Poh CL
Med Microbiol Immunol; 2021 Feb; 210(1):1-11. PubMed ID: 33515283
[TBL] [Abstract][Full Text] [Related]
18. A recombinant, chimeric tetravalent dengue vaccine candidate based on a dengue virus serotype 2 backbone.
Osorio JE; Wallace D; Stinchcomb DT
Expert Rev Vaccines; 2016; 15(4):497-508. PubMed ID: 26635182
[TBL] [Abstract][Full Text] [Related]
19. Expression and purification of an immunogenic dengue virus epitope using a synthetic consensus sequence of envelope domain III and Saccharomyces cerevisiae.
Nguyen NL; Kim JM; Park JA; Park SM; Jang YS; Yang MS; Kim DH
Protein Expr Purif; 2013 Apr; 88(2):235-42. PubMed ID: 23376461
[TBL] [Abstract][Full Text] [Related]
20. Virus-like particles derived from Pichia pastoris-expressed dengue virus type 1 glycoprotein elicit homotypic virus-neutralizing envelope domain III-directed antibodies.
Poddar A; Ramasamy V; Shukla R; Rajpoot RK; Arora U; Jain SK; Swaminathan S; Khanna N
BMC Biotechnol; 2016 Jun; 16(1):50. PubMed ID: 27301568
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
